GeneHealth - Your precision medicine

Hyperargininemia

Disease Details

Family Health Simplified

Buy Membership

Description: Hyperargininemia is a rare metabolic disorder characterized by an excessive buildup of the amino acid arginine in the blood due to a deficiency of the enzyme arginase.
Type: Hyperargininemia is an inherited metabolic disorder characterized by an excess of the amino acid arginine in the blood. It follows an autosomal recessive pattern of genetic transmission.
Signs And Symptoms: The presentation of argininemia, in those that are affected, is consistent with the following:
Prognosis: Hyperargininemia is a rare genetic disorder characterized by the body's inability to break down the amino acid arginine due to a deficiency in the enzyme arginase.

**Prognosis:** The prognosis for hyperargininemia varies and depends on the timing and effectiveness of treatment. Early diagnosis and prompt initiation of a low-arginine diet along with other medical interventions can improve outcomes and potentially prevent severe complications. However, if left untreated or if treatment is inadequate, hyperargininemia can lead to progressive neurological deterioration, developmental delays, spasticity, and other severe health issues.

**Needs and Approaches to Novel Advances (NAN):**
1. **Gene Therapy:** Research into gene therapy aims to correct the underlying genetic defect, potentially offering a permanent cure for hyperargininemia.
2. **Enzyme Replacement Therapy:** Development of enzyme replacement therapies could provide an external source of the missing arginase enzyme, aiding in the management of the disease.
3. **Precision Medicine:** Advances in precision medicine may pave the way for more tailored treatments based on individual genetic profiles, leading to improved management and outcomes.

Continued research and investment in these areas are crucial for the development of more effective treatments for hyperargininemia.
Onset: For hyperargininemia, the onset of symptoms typically occurs in early childhood, often between the ages of 1 and 3 years.
Prevalence: Hyperargininemia is a rare metabolic disorder caused by a deficiency of the enzyme arginase, which is part of the urea cycle. The exact prevalence is unknown, but it is estimated to be very rare, occurring in less than 1 in 1,000,000 live births.
Epidemiology: Hyperargininemia is a rare autosomal recessive disorder. The global prevalence is not well-documented due to its rarity, but it occurs in an estimated 1 in every 2,000,000 live births. It is caused by mutations in the ARG1 gene, which leads to a deficiency of the enzyme arginase. This enzyme deficiency results in elevated levels of arginine in the blood and various neurological and developmental issues.
Intractability: Hyperargininemia is characterized by elevated levels of arginine in the blood due to a deficiency in the enzyme arginase, which is part of the urea cycle. While the condition can be managed with dietary restrictions and medical interventions to reduce arginine levels and prevent complications, it can still be challenging to control completely. Consequently, it is considered a serious and difficult-to-treat condition, especially if not diagnosed and managed early.
Disease Severity: Hyperargininemia is a rare inherited disorder that affects the urea cycle, leading to elevated levels of arginine in the blood.

- **Disease Severity:** The severity of hyperargininemia can vary, but it often leads to severe neurological symptoms, including developmental delay, spasticity, seizures, and intellectual disability. Early diagnosis and treatment can mitigate some of the neurological complications.

- **Nan:** In this context, "nan" doesn't seem to directly apply to the context of hyperargininemia. However, if you are referring to "neuronal apoptosis/neurodegeneration," these phenomena can be associated with the severe neurological symptoms seen in untreated hyperargininemia.
Healthcare Professionals: Disease Ontology ID - DOID:9278
Pathophysiology: Hyperargininemia is a rare metabolic disorder resulting from a deficiency of the enzyme arginase, which is involved in the urea cycle. The condition leads to elevated levels of arginine in the blood. Normally, arginase converts arginine into ornithine and urea; a deficiency disrupts this process, causing an accumulation of arginine and a decrease in the production of urea, leading to hyperammonemia.

The excess arginine and ammonia can cause neurological symptoms, developmental delays, spasticity, and growth retardation. If untreated, hyperargininemia can be severe and include progressive neurological impairment. Early diagnosis and dietary management focusing on protein restriction can help mitigate the symptoms and improve quality of life.
Carrier Status: Carrier status for hyperargininemia means that a person carries one mutated copy of the gene associated with this condition but does not typically exhibit symptoms. Carriers can pass the gene to their offspring, potentially resulting in the disorder if the other parent also passes down a mutated gene.
Mechanism: Hyperargininemia is a rare inherited disorder that affects the urea cycle, a series of biochemical reactions that occur in the liver to remove ammonia from the body. Here are the key points related to its mechanism and molecular mechanisms:

**Mechanism:**
1. **Gene Mutation:** Hyperargininemia is caused by mutations in the ARG1 gene that encodes the enzyme arginase 1.
2. **Urea Cycle Disruption:** Arginase 1 is responsible for the final step in the urea cycle, which converts arginine into ornithine and urea. When arginase 1 is deficient or dysfunctional due to mutations, arginine accumulates in the blood.
3. **Ammonia Accumulation:** Ineffective conversion of arginine leads to a buildup of ammonia, which is toxic, particularly to the brain.

**Molecular Mechanisms:**
1. **Mutation Types:** Different types of mutations (missense, nonsense, frameshift, or splice site mutations) can affect the structure and function of the arginase 1 enzyme.
2. **Enzyme Activity:** The mutations in ARG1 result in either a loss or significant reduction of enzyme activity, which impedes the conversion of arginine to ornithine and urea.
3. **Metabolic Consequences:** Elevated arginine and ammonia levels can interfere with neurotransmission and energy metabolism. High arginine may also induce oxidative stress and disrupt mitochondrial functions.
4. **Toxicity and Symptoms:** The accumulating ammonia and altered arginine metabolism lead to neurological symptoms, including spasticity, developmental delays, intellectual disability, and other systemic complications.

Understanding these molecular mechanisms provides insight into potential therapeutic strategies, such as enzyme replacement therapies, dietary modifications, or gene therapy, to manage the disease effectively.
Treatment: The treatment for people with argininemia includes:
Sodium benzoate
Sodium phenylbutyrate
Carglumic acid
Glycerol phenylbutyrate
Palonosetron
Ondansetron hydrochloridePegzilarginase (Loargys) was approved for medical use in the European Union in December 2023.
Compassionate Use Treatment: Hyperargininemia is a rare metabolic disorder characterized by elevated levels of arginine in the blood due to a deficiency in the enzyme arginase.

For compassionate use treatment or off-label/experimental treatments, the primary approach focuses on managing the symptoms through dietary restrictions, including a low-protein diet and the use of amino acid supplements that do not contain arginine.

There are currently no widely recognized or established compassionate use treatments specifically for hyperargininemia beyond dietary management. However, experimental treatments may include enzyme replacement therapy or gene therapy, but these approaches are still largely in the research phase and not yet widely available.

Patients with hyperargininemia should be managed by a specialist familiar with metabolic disorders to explore any new and emerging treatments.
Lifestyle Recommendations: Lifestyle recommendations for managing hyperargininemia include dietary modifications to limit arginine intake. This involves avoiding high-protein foods and focusing on low-protein alternatives. Additionally, it is essential to maintain regular follow-ups with healthcare providers, including dietitians and metabolic specialists, to monitor and adjust the diet as needed. Staying hydrated and avoiding fasting can also help manage symptoms. Regular exercise and maintaining a healthy weight can further support overall well-being.
Medication: Hyperargininemia is a rare inherited disorder characterized by elevated levels of arginine in the blood due to a deficiency in the enzyme arginase. There are no specific medications to cure hyperargininemia, but management typically involves dietary modifications to reduce protein intake and supplementation with essential amino acids that are deficient. Additionally, some patients may require medications to manage symptoms or address complications. Consultation with a metabolic specialist or geneticist is recommended for individualized treatment plans.
Repurposable Drugs: There is no widely recognized list of repurposable drugs specifically for hyperargininemia. This genetic disorder, which results from a deficiency of the enzyme arginase, leads to an accumulation of arginine and related compounds. Current management primarily focuses on dietary restrictions to limit arginine intake and prevent hyperammonemia. Any potential drug therapy would need to be aimed at either reducing arginine levels or mitigating the effects of its accumulation, but specific drugs are not established for this purpose as of now.
Metabolites: Hyperargininemia is characterized by elevated levels of arginine in the blood. Deficient activity of the enzyme arginase, which converts arginine to ornithine and urea in the urea cycle, leads to this condition. This results in the accumulation of arginine and often secondary increases in other urea cycle intermediates, such as citrulline. Other metabolic abnormalities may include elevated levels of ammonia (hyperammonemia) due to the disrupted urea cycle.
Nutraceuticals: For hyperargininemia, there are no specific established nutraceutical treatments. The condition, which is an inherited metabolic disorder resulting from a deficiency in the enzyme arginase, typically necessitates dietary and medical management to control the levels of arginine in the blood. The primary approach involves a low-protein diet supplemented with essential amino acids free from arginine. Any consideration of nutraceuticals should be under the guidance of a healthcare professional. As of now, there is no significant data or established evidence of nanotechnology (nan) applications specifically targeting hyperargininemia.
Peptides: In hyperargininemia, a rare metabolic disorder, affected individuals have an elevated level of arginine in the blood due to a deficiency in the enzyme arginase. As a result, the normal breakdown process of arginine is disrupted.

Regarding peptides, hyperargininemia does not directly affect peptide levels but the elevated arginine might impact certain biochemical pathways involving peptide synthesis and catabolism.

"Nan" usually refers to nanoparticles or nanotechnology; however, if "nan" is intended to be an abbreviation or code in your context, please provide more details for precise information. Generally, nanotechnology approaches in hyperargininemia are in experimental or theoretical stages and might focus on delivering therapeutic enzymes or targeted treatments at the cellular level.